The Current Status at Shionogi

September 2008
Merrill Lynch Japan Conference

Isao Teshirogi, Ph.D.
President and Representative Director

SONG for you!

SHIONOGI & CO., LTD.
Disclaimer

THESE MATERIALS CONTAIN CERTAIN FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY WORDS SUCH AS ‘BELIEVES’, ‘EXPECTS’, ‘ANTICIPATES’, ‘PROJECTS’, ‘INTENDS’, ‘SHOULD’, ‘SEEKS’, ‘ESTIMATES’, ‘FUTURE’ OR SIMILAR EXPRESSIONS OR BY DISCUSSION OF, AMONG OTHER THINGS, STRATEGY, GOALS, PLANS OR INTENTIONS. VARIOUS FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY IN THE FUTURE FROM THOSE REFLECTED IN FORWARD-LOOKING STATEMENTS CONTAINED IN THIS DOCUMENT, AMONG OTHERS: (1) MACROECONOMIC CONDITION AND GENERAL INDUSTRY CONDITIONS SUCH AS THE COMPETITIVE ENVIRONMENT FOR PHARMACEUTICAL COMPANIES; (2) REGULATORY AND LITIGATION MATTERS AND RISKS; (3) LEGISLATIVE DEVELOPMENTS; (4) CHANGES IN TAX AND OTHER LAWS AND THE EFFECT OF CHANGES IN GENERAL ECONOMIC CONDITIONS; (5) THE RISK THAT A CONDITION TO CLOSING OF THE TRANSACTION MAY NOT BE SATISFIED; (6) THE RISK THAT A REGULATORY APPROVAL THAT MAY BE REQUIRED FOR THE TRANSACTION IS NOT OBTAINED OR IS OBTAINED SUBJECT TO CONDITIONS THAT ARE NOT ANTICIPATED; AND (7) OTHER RISKS TO CONSUMMATION OF THE TRANSACTION.

RISKS AND UNCERTAINTIES ARE PARTICULARLY SIGNIFICANT WITH RESPECT TO FORWARD-LOOKING STATEMENTS RELATED TO EXISTING PRODUCTS AND PRODUCTS CURRENTLY UNDER DEVELOPMENT. SUCH RISKS AND UNCERTAINTIES INCLUDE, BUT ARE NOT LIMITED TO, COMPLETION OR TERMINATION OF CLINICAL TRIALS, APPROVALS FROM REGULATORY AUTHORITIES, CLAIMS OR CONCERNS RELATING TO PRODUCT SAFETY OR EFFECTIVENESS, TECHNOLOGICAL ADVANCES. EXISTING PRODUCTS ALSO INVOLVE RISKS RELATING TO MANUFACTURING AND MARKETING WHICH INCLUDE, BUT ARE NOT LIMITED TO, THE INABILITY TO MEET DEMAND, DIFFICULTY IN SECURING RAW MATERIALS, AND INDUSTRY COMPETITION.

WE DO NOT UNDERTAKE ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE, EVEN IN THE EVENT THAT SUCH UPDATES ARE DESIRABLE.

THIS PRESENTATION INCLUDES INFORMATION CONCERNING PHARMACEUTICALS (INCLUDING PRODUCTS CURRENTLY UNDER DEVELOPMENT). SUCH INFORMATION IS NOT BEING PROVIDED FOR THE PURPOSE OF ADVERTISING OR TO PROVIDE MEDICAL ADVICE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THESE MATERIALS ARE FOR INFORMATIONAL PURPOSES ONLY AND DO NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL SCIELE PHARMA’S COMMON STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) THAT WAS FILED BY TALL BRIDGE, INC. WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC). THESE MATERIALS, AND AS AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER, THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. INVESTORS AND STOCKHOLDERS CAN OBTAIN A FREE COPY OF THESE MATERIALS AND OTHER DOCUMENTS FILED BY TALL BRIDGE, INC. WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. THE TENDER OFFER MATERIALS MAY ALSO BE OBTAINED FOR FREE BY CONTACTING THE INFORMATION AGENT FOR THE TENDER OFFER, GEORGESON, AT 1-212-440-9800 FOR BANKS AND BROKERS OR 1-800-334-9586 FOR SHAREHOLDERS AND ALL OTHERS, OR BY WRITING TO: 199 WATER STREET, 26TH FLOOR, NEW YORK, NY 10038.
Establishment of the 2nd Medium-Term Business Plan

The 1st Medium-Term Business Plan  
(April 2000—March 2005)  
~ Concentration on the prescription drug business ~

The 2nd Medium-Term Business Plan  
(April 2005—March 2010)  
~ Entering a stage to accelerate toward significant growth ~

- Full contribution of Crestor®  
  (royalty income and domestic sales)
- Activating R&D activities
- Launching new products in domestic market  
  (10 products in total)
Consolidated Financial Targets for the 2nd Medium-Term Business Plan

- **Net sales**
  - FY2005: 196.3
  - FY2006: 199.7
  - FY2007: 214.2
  - FY2008E: 231.0
  - FY2009E: 270.0

- **R&D expenses**
  - FY2005: 32.2
  - FY2006: 37.5
  - FY2007: 40.2
  - FY2008E: 48.0
  - FY2009E: 50.0

- **Operating income**
  - FY2005: 29.2
  - FY2006: 28.8
  - FY2007: 40.3
  - FY2008E: 48.0
  - FY2009E: 80.0

- **Net income**
  - FY2005: 22.7
  - FY2006: 18.5
  - FY2007: 25.0
  - FY2008E: 30.0
  - FY2009E: 48.0
Expansion of Crestor® Sales

Expansion of royalty income and domestic sales

- Royalty income
  - Global sales by AstraZeneca increased
    (Unit: billion dollar)

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>1H 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crestor Global Sales</td>
<td>2.0</td>
<td>2.8</td>
<td>1.68</td>
</tr>
</tbody>
</table>

- Domestic sales
  - Market share increased smoothly

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crestor Total</td>
<td>4.0</td>
<td>5.3</td>
<td>11.2</td>
</tr>
<tr>
<td>4Q</td>
<td>4.0</td>
<td>5.3</td>
<td></td>
</tr>
<tr>
<td>1Q</td>
<td>5.3</td>
<td>7.0</td>
<td>11.2</td>
</tr>
<tr>
<td>2Q</td>
<td>7.0</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>3Q</td>
<td>8.5</td>
<td>10.5</td>
<td></td>
</tr>
<tr>
<td>4Q</td>
<td>10.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY2006</td>
<td>19.4</td>
<td>29.8</td>
<td>38.8</td>
</tr>
<tr>
<td>FY2007</td>
<td>2.5</td>
<td>10.4</td>
<td>19.0</td>
</tr>
<tr>
<td>FY2008E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Based on NHI Price)
<table>
<thead>
<tr>
<th>Three targeted R&amp;D areas</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infectious Diseases</strong></td>
<td><strong>Pain</strong></td>
</tr>
<tr>
<td><strong>Metabolic Syndrome</strong></td>
<td><strong>Others</strong></td>
</tr>
<tr>
<td><strong>Frontier areas</strong></td>
<td><strong>Allergies</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Filing</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Finibax</strong>&lt;sup&gt;®&lt;/sup&gt; (FY2005)</td>
<td></td>
</tr>
<tr>
<td><strong>Avelox</strong>&lt;sup&gt;®&lt;/sup&gt; (FY2005)</td>
<td></td>
</tr>
<tr>
<td><strong>OxiNorm</strong>&lt;sup&gt;®&lt;/sup&gt; (FY2006)</td>
<td></td>
</tr>
<tr>
<td><strong>Crestor</strong>&lt;sup&gt;®&lt;/sup&gt; (FY2005)</td>
<td><strong>Irbetan</strong>&lt;sup&gt;®&lt;/sup&gt; (Hypertension) (Launch, July 2008)</td>
</tr>
<tr>
<td><strong>Claritin</strong>&lt;sup&gt;®&lt;/sup&gt; (New formulation) (FY2007)</td>
<td></td>
</tr>
<tr>
<td><strong>Pirfenidone</strong> (Idiopathic Pulmonary Fibrosis) (FY2008)</td>
<td><strong>Differin</strong>&lt;sup&gt;®&lt;/sup&gt; (Acne vulgaris) (Approval, July 2008)</td>
</tr>
<tr>
<td><strong>Duloxetine</strong> (Depression) (FY2009)</td>
<td><strong>Cetrotide</strong>&lt;sup&gt;®&lt;/sup&gt; (FY2006)</td>
</tr>
</tbody>
</table>

**Growth Driver beyond 2010**

- **Crestor**<sup>®</sup>
- **Irbetan**<sup>®</sup>
- **Duloxetine**
Growth Driver beyond 2010

**Irbetan® (Hypertension)**
- Approved in 109 countries and launched in 86 countries worldwide by Sanofi-Aventis and Bristol Myers Squibb as of today
- ARB* market in Japan has grown by double digits every year

**Duloxetine (Depression & DNP)**
- Approved for depression in more than 90 countries, and for DNP (diabetic peripheral neuropathic pain) in more than 70 countries
- The market of treatment for depression has been expanding

---

**ARB market in Japan**
(IMS data)

- FY2005: 390 billion yen
- FY2006: 420 billion yen
- FY2007: 490 billion yen

**Market of treatment for depression**
(IMS data)

- FY2005: 99.7 billion yen
- FY2006: 108.2 billion yen
- FY2007: 119.7 billion yen

* Angiotensin II receptor blocker
Overseas Strategy

Second Medium-term Management Plan

- Acquire at least 5 products in Phase II or later by the end of FY 2009
- Simultaneous development of multiple proprietary products in Japan, the U.S., and Europe
- Forge strategic alliances for each product

Medium/Long-term Goals

- Establish a sales infrastructure in the U.S.
- Continued expansion of the proprietary product pipeline
- Educate personnel to enable adaptation to globalization
Pipeline of Proprietary Global Development:
Development Goals for FY 2009

- Steady progress in clinical trials of proprietary products
- Increased focus on establishing an overseas infrastructure

3 Core Domains
- Infectious Diseases
- Pain
- MS

New Domains
- Allergies
- Other

Products resulting from proprietary global development efforts

* Allergic rhinitis, asthma, etc.
** Idiopathic thrombocytopenic purpura, hepatitis C, carcinoma chemotherapy, etc.
### Overview of Sciele: High Growth Rate and Stable Profitability

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (USD in millions)</th>
<th>Operating Profit (USD in millions)</th>
<th>Net Income (USD in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>$152</td>
<td>$38</td>
<td>$27</td>
</tr>
<tr>
<td>2005</td>
<td>$216</td>
<td>$59</td>
<td>$39</td>
</tr>
<tr>
<td>2006</td>
<td>$293</td>
<td>$65</td>
<td>$45</td>
</tr>
<tr>
<td>2007</td>
<td>$382</td>
<td>$78</td>
<td>$45</td>
</tr>
</tbody>
</table>

**CAGR** = Compound Annual Growth Rate during 2004-2007

Source: Company disclosures, 2007 SEC 10K Filings
## Overview of Sciele: Sciele’s Strengths

### Sales and Marketing Capability
- Over 700 sales representatives across the U.S.
- Ability to retain capable personnel and enhance sales capabilities based on performance-based compensation and clear quantitative targets
- Ability to maintain product prices based on strong relationships and negotiations with healthcare organizations

### Product Portfolio
- Balanced portfolio built around products in the cardiovascular disease, diabetes, women’s health, and pediatrics domains
- Stable growth and profitability in each area of specialization

### Sourcing/Launching Pipeline Products
- Focusing on niche products in Phase II and III of development
- Business development team has an industry-wide network and has know-how based on many years of experience
- Speedy acquisition of pipeline products and proven ability to bring pipeline products to market

### Experienced Management and Personnel
- Speedy decision-making and execution
- Strong experience in the pharmaceutical industry
- Strong leadership and teamwork

**High growth rate and stable profitability**
Expected Benefits from the Acquisition

- **Significant strengthening of U.S. sales infrastructure**
  - Immediate addition of a nationwide sales network of over 700 MRs
- **Reduce overall time and expense required to establish and advance a U.S. sales infrastructure**
  - Leverage strong know-how concerning product launch and sales in the U.S.
- **Pursue synergies based on complementary product domains**
  - Proven track record of both Shionogi and Sciele in areas of focus, such as the cardiovascular disease and diabetes domains
- **Enhanced profitability based on proprietary sales of strong pipeline products**
  - Ability to develop proprietary pipeline products in addition to allowing for sales efforts in the U.S.
- **Potential to advance skills of Shionogi personnel**
  - Access to a Sales team with proven track record in the U.S. market
Toward the Achievement of the 2nd Medium-Term Business Plan

- Further concentration on research and development area
  - S-2367 / S-349572 / S-777469
  - S-555739 / S-888711
  - Scheduled to move another 3 novel compounds to Phase I within FY2008

- Steady development of domestic sales: improvement of SFE
  - Crestor® / Irbetan®
  - New products: Finibax® / Defferine® / Pirfenidone

- Smooth transition of Sciele
Reference Materials

- Pipeline
- Overview of Sciele Pharma, Inc.
Pipeline
Drug Pipeline (As of September, 2008)

<table>
<thead>
<tr>
<th>Three targeted R&amp;D areas</th>
<th>Infectious Diseases</th>
<th>Pain</th>
<th>Metabolic Syndrome</th>
<th>Allergies</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ph I/Ph IIa</strong></td>
<td>S-013420 (Bacterial infection)</td>
<td>Finibax* (Pediatric infection)</td>
<td>Doripenem (EU/US RTI)</td>
<td>Diflucan* (EUS RTI)</td>
<td>In-house products globally</td>
</tr>
<tr>
<td><strong>Ph IIb</strong></td>
<td>S-021812 (Peramivir) (Influenza)</td>
<td>Finibax* (New dosage regimen)</td>
<td>Doripenem (US cIAI, cUTI)</td>
<td>In-licensed</td>
<td></td>
</tr>
<tr>
<td><strong>Ph III</strong></td>
<td>S-2367 (Anti-obesity drug)</td>
<td>Duloxetine (DNP)</td>
<td>S-0139 (Cerebrovascular diseases)</td>
<td>In-licensed</td>
<td></td>
</tr>
<tr>
<td><strong>Filing</strong></td>
<td>S-3013 (Atherosclerosis)</td>
<td>Claritin* (New formulation)</td>
<td>S-888711 (Thrombocytopenia)</td>
<td>Out-licensed</td>
<td></td>
</tr>
<tr>
<td><strong>Launch</strong></td>
<td>S-7/7/469 (Atopic dermatitis)</td>
<td>Crestor* (Hypertension)</td>
<td>S-0373 (Spinocerebellar ataxia)</td>
<td>Out-licensed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-555739 (Allergic disease)</td>
<td>Irbetan* (Hypertension)</td>
<td>S-0139 (Cerebrovascular diseases)</td>
<td>Out-licensed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-777469 (Atherosclerosis)</td>
<td>Claritin* (Pediatric infection)</td>
<td>S-0139 (Cerebrovascular diseases)</td>
<td>Out-licensed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-349572/S-265744/ S-247303 (HIV infection)</td>
<td>Diflucan* (EUS RTI)</td>
<td>NS75B (Benign Prostatic Hypertrophy)</td>
<td>Out-licensed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-349572/S-265744/ S-247303 (HIV infection)</td>
<td>Diflucan* (EUS RTI)</td>
<td>NS75A (Uterine Myoma)</td>
<td>Out-licensed</td>
<td></td>
</tr>
</tbody>
</table>

DNP: Diabetic Neuropathic Pain, RTI: Respiratory Tract Infection, cIAI: complicated Intra-Abdominal Infections, cUTI: complicated Urinary Tract Infections including pyelonephritis
S-2367: Profile

- Anti-obesity (oral)
- Neuropeptide Y Y5 receptor antagonist
- Key findings from pre-clinical studies
  - Increased energy consumption
  - Suppressed visceral fat accumulation and improved blood glucose and serum lipid levels
  - Expected product profile: sustainable weight suppression without rebound
  - Confirmed excellent safety
- Key findings from clinical studies to date
  - Once-daily administration (T½: about 20 hours)
  - Achieved positive Phase IIa proof of concept in the USA study
  - Favorable safety profiles without adverse effects on central nervous system
    - No effect on depression or anxiety scores

Phase IIb studies in progress in the US
Neuropeptide Y (NPY) in the brain plays a significant role in energy homeostasis. The NPY-Y5 system has been implicated as a key regulator of energy homeostasis. Function of NPY through Y5 receptor:
1. Appetite (energy intake) ↑
2. Energy expenditure ↓

Modern life style, high-calorie food, etc. lead to:
- Overactivation of NPY-Y5 system
- Disorder of energy homeostasis
- Obesity

S-2367
NPY-Y5 receptor antagonist Normalize NPY-Y5 system
**S-2367: Outline of Phase IIb Study**

- **Study 1**
  - RCD (reduced calorie diet) lead-in followed by RCD with S-2367 or placebo treatment
  - Number of patients: 750
  - Maximum dose: 1600 mg

- **Study 2**
  - LCD (low calorie diet) lead-in followed by RCD with S-2367 or placebo treatment
  - Number of patients: 750
  - Maximum dose: 1600 mg

- **To assess efficacy and safety of treatment over a one-year period**
  - Reduce Phase III development risk
  - Interim analysis at 6 month time point
  - Completion of drug treatments: within 2008

---

**May 2008, Shionogi received the recommendation that both RCD and LCD studies (both dose arms) should continue**
Developed by Shionogi-GlaxoSmithKline Pharmaceuticals, LLC

HIV Integrase Inhibitor (oral)

Characteristics

- Strong anti-HIV activity in inhibiting virus replication \textit{in vitro}
- Good resistant virus profile \textit{in vitro}
- Good pharmacokinetic profile
- Low risk of drug-drug interactions

Marketability

- Estimated 33 million HIV patients worldwide

\textbf{Started Phase IIa for S-349572 in June, 2008}
S-349572: In vitro Activity against Highly Resistant Viruses for Preceding Competitor’s Compound

* Resistance mutations reported in clinical trials of preceding competitor’s compound
**S-777469: Profile**

- **Indication:** Atopic dermatitis (AD)
- **Selective cannabinoid 2 receptor agonist (oral)**
- **Characteristics (non-clinical)**
  - Reduces scratching behavior induced by various pruritic agents in mouse model
  - Improves dermatitis scores in animal AD model
  - Good safety profile
- **Positioning**
  - First-in-Class therapeutic agent for AD
- **Marketability**
  - Predicted number of patients with eczema/dermatitis including AD is 30 million (Japan, the USA, the EU)

**Phase IIa studies in progress both in Japan and the US**
**S-777469: Mechanism of Action**

- **Antigen**
  - Scratching
  - Histamine
  - Substance P
  - Other mediators

- **Inflammation**
  - Nerves related to transmission of pruritus (c-fiber)
  - CB2 receptor
  - Anti-inflammatory effect through direct action on inflammatory cells
  - Prevent becoming chronic of atopic dermatitis by blocking both inflammation and pruritus

- **Antihistamines**
  - Supress inflammation
  - Block transmission of pruritus

- **CB2 receptor**
  - Anti-pruritic effect by directly suppressing c-fiber firing
  - More potent anti-pruritic effect can be expected than antihistamine products

- **S-777469**
  - Itch-scratch cycle

- **Spinal Cord**
  - Brain
Update of Phase I studies

- **Japan**
  - Completed a 14-day, multiple-dose study in healthy volunteers
    - Good tolerability
    - Dose-dependent increase in plasma concentration from 50 to 800 mg
- **USA**
  - Conducting a 14-day, multiple-dose study in patients with atopic dermatitis (Phase Ib/IIa)
    - Treatment completed

Update of Phase II studies

- **Japan**
  - Phase IIa study
    - Patients enrolment commenced in Jan. 2008
    - Pruritus and skin manifestations to be evaluated as primary endpoints
    - Top-line results: 3Q 2008 (scheduled)
- **USA**
  - Phase IIa study (Atopic dermatitis)
    - Top-line results: 2Q 2009 (scheduled)
S-555739: Profile

- **Indication:** Allergic rhinitis (as the first indication target)
- **Prostaglandin D2 receptor antagonist (oral)**
  - Backup compound of S-5751: More potent receptor antagonist activity and good pharmacokinetic profile
- **Characteristics (non-clinical)**
  - More suppressive effect against nasal congestion than existing anti-allergy drugs
  - Effective with once-daily dosing
  - Good safety profile
- **Positioning**
  - New therapeutic drug against nasal congestion that is not relieved by existing anti-allergy drugs
- **Marketability**
  - Predicted total number of allergic rhinitis patients in Japan, the USA, and the EU is 64 million, 60% of which are estimated to have nasal congestion

Phase I studies are ongoing both in Japan and Europe
S-555739 strongly suppressed antigen-induced nasal congestion, and the efficacy of S-555739 was much stronger than that of existing anti-allergy drugs.
S-888711: Profile

- Indications: Various diseases with thrombocytopenia
- Thrombopoietin receptor agonist (oral)
- Potential pharmacological properties from non-clinical studies
  - Excellent efficacy and safety with once-daily dosing
  - No food effects
  - More moderate dose-response curve than preceding compounds
- Development stage
  - Phase I single dose study (Japan): in progress
    - Good pharmacokinetic profiles; increases Cmax and AUC dose-dependently
    - Good tolerability up to the maximum dose

Phase I multiple dose study in preparation in Japan
S-7701 (Pirfenidone): Profile

- Licensed from Marnac, Inc., (USA) and KDL, Inc. (Japan)
- Indication: Idiopathic pulmonary fibrosis
- Anti-fibrosis (oral)
  - Significantly prevented worsening of vital capacity vs. placebo
- Designated as an orphan drug
- NDA filed in Mar. 2007
  - Completed onsite GCP compliance inspection at Medical Institutions and Shionogi
  - May 2008: American Thoracic Society (ATS), Toronto
    - Announced results of Phase III

Under review by the agency
S-021812 (Peramivir): Profile

- Licensed from BioCryst Pharmaceuticals, Inc. (USA)
- Anti-influenza virus drug (neuraminidase inhibitor) (injection)
- Characteristics
  - Highly active against influenza A and B viruses
    - More potent against influenza B virus than Tamiflu®
  - Strong activity against highly pathogenic avian influenza virus (H5N1)
  - Strong affinity to influenza neuraminidase and slow off-rate
    → Possibly effective with a single-dose administration
  - Potency of “Delay Dosage” (administration later than 48 hrs after onset of infection)
  - Broad indications from ordinary seasonal influenza to severe or life-threatening influenza
  - Award of US$102.6 million from DHHS* to BioCryst for advanced development of peramivir.
  - Designated as a Drug Product for Priority Consultation in Japan

Phase III study in preparation

* The U.S. Department of Health and Human Services
Results of Phase II Study (Intravenous Injection)

- **Indication**
  - Influenza virus infection

- **Study design**
  - Multicenter, double-blind, placebo controlled study
  - Administration of 300mg and 600mg

- **Efficacy**
  - Confirmed its primary endpoint of improvement in the median time to alleviation of symptoms compared to placebo alone

- **Safety**
  - Generally well-tolerated

Developing a subcutaneous formulation for potential market
Overview of Sciele Pharma, Inc.
Established in 1992 in the U.S., listed on the NASDAQ since 2000

Nationwide operations, based in Atlanta, Georgia

Engages in the development and sales of prescription drugs in the cardiovascular disease, diabetes, women’s health, and pediatrics domains

- Acquires rights to manufacture and market products from development partners
- Proven ability to bring products in later phases to the market
- Strong nationwide sales network

Total number of employees: 920 (as of 12/31/2007)

- Of which, sales reps: 770
Overview of Sciele: Sales Force Productivity

Number of Sales Reps and Revenue per Sales Rep

(USD in thousands)

Source: Company disclosures, 2007 SEC 10K Filings
# Overview of Sciele: Product Portfolio, Pipeline and Sales Force

<table>
<thead>
<tr>
<th>Sales Force</th>
<th>Key Products</th>
<th>Major Pipeline Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>• Sular CR (Nisoldipine) with Geomatrix Delivery System</td>
<td>• CloniBID (Phase III)</td>
</tr>
<tr>
<td>(223)</td>
<td>• Nitrolingual Pumpspray</td>
<td>• Duochol (Phase III)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>• Prandin</td>
<td>• ADX-415 (Phase II)</td>
</tr>
<tr>
<td>(174)</td>
<td>• Fortamet</td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td>• Fenoglide</td>
<td></td>
</tr>
<tr>
<td>(177)</td>
<td>• PrandiMet (market launch planned during the current fiscal year)</td>
<td></td>
</tr>
<tr>
<td>Pediatrics</td>
<td>• Prenate Family (DHA and Elite)</td>
<td>• PSD502 (Phase III)</td>
</tr>
<tr>
<td>(144)</td>
<td>• Zovirax Ointment and Cream</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fosteum</td>
<td></td>
</tr>
<tr>
<td>Sales Division</td>
<td>• Allegra OS, Allegra ODT</td>
<td>• Xytril (Completed Phase III safety trials)</td>
</tr>
<tr>
<td>(718 sales reps)</td>
<td>• Orapred ODT</td>
<td>• Head Lice Treatment (Phase III)</td>
</tr>
<tr>
<td></td>
<td>• Twinject</td>
<td>• Clonicel (Phase III)</td>
</tr>
<tr>
<td></td>
<td>• Methylin OS/CT</td>
<td></td>
</tr>
</tbody>
</table>

Source: Company disclosures, Company website. Headcount data from Sciele’s presentation material at Healthcare Conference held by Bank of America (5/13/2008)
# Overview of Sciele: Experienced Management Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Industry Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick P. Fourteau</td>
<td>Chief Executive Officer and Director</td>
<td>Over 25 years of industry experience, including years at Eli Lilly</td>
</tr>
<tr>
<td>Edward Schutter</td>
<td>Chief Operating Officer</td>
<td>Over 20 years of industry experience, including years at Solvay</td>
</tr>
<tr>
<td>Joseph J. Ciaffoni</td>
<td>Chief Commercial Officer</td>
<td>Over 15 years of industry experience, including years at Novartis</td>
</tr>
<tr>
<td>Darrell Borne</td>
<td>Chief Financial Officer</td>
<td>Over 15 years of experience in financial management, including years at Exxon/Mobil</td>
</tr>
<tr>
<td>Larry M. Dillaha M.D.</td>
<td>Chief Medical Officer</td>
<td>Over 15 years of industry experience, including years at Sanofi-Aventis</td>
</tr>
<tr>
<td>Leslie Zacks</td>
<td>Chief Legal and Compliance Officer</td>
<td>Over 15 years of legal experience including years at Hunton &amp; Williams LLP</td>
</tr>
</tbody>
</table>

Source: Company disclosures, company website
### Sciele’s Key Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Domain</th>
<th>Overview</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sular / Sular CR</strong></td>
<td><strong>Cardiovascular</strong></td>
<td>◆ Sular is a dihydropyridine (DHP) calcium channel blocker that lowers blood pressure and provides consistent 24-hour control of hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ A new Sular formulation was approved by the FDA in January 2008 and is now available in four lower dosage strengths</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ Sular can be used alone or in combination with ACE inhibitors, beta blockers and diuretics</td>
</tr>
<tr>
<td><strong>Nitrolingual Pumpspray</strong></td>
<td><strong>Cardiovascular</strong></td>
<td>◆ This oral nitroglycerin spray offers acute relief in the event of heart attack or chest pain caused by coronary artery disease, a condition that affects 9.1 million Americans, according to the American Heart Association</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ Nitrolingual Pumpspray is formulated to deliver fast pain relief with simple and reliable administration</td>
</tr>
</tbody>
</table>

Source: Company disclosures, Company website
### Sciele’s Key Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Domain</th>
<th>Overview</th>
</tr>
</thead>
</table>
| Triglide     | Diabetes | ◆ Triglide offers an effective oral treatment for lipid disorders such as elevated cholesterol and triglycerides  
◆ It can be administered under both fed and fasting conditions, allowing patients to take the drug at any time, which contributes to improved compliance |
| Fenoglide    | Diabetes | ◆ Fenoglide offers the lowest dose of fenofibrate currently available on the market for the treatment of hyperlipidemia and hypertriglyceridemia  
◆ Available in tablet form and two dosage strengths, Fenoglide utilizes LifeCycle Pharma’s MeltDose® technology, which is designed to enhance absorption and bioavailability. |

Source: Company disclosures, Company website
## Sciele’s Major Pipeline Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Domain</th>
<th>Overview</th>
</tr>
</thead>
<tbody>
<tr>
<td>CloniBID</td>
<td>Cardiovascular</td>
<td>- Product: Extended release clonidine HCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Indication: Hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Market: Approx. 13mn TRx’s written for clonidine products in 2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Benefits: 12 hour, sustained release formulation; little to no drowsiness, somnolence, or sedation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Status: PDUFA date of December 19, 2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- IP: Issued U.S. patent-expires in October 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Opportunity: Better formulation of an established anti-hypertensive</td>
</tr>
<tr>
<td>ADX-415</td>
<td>Cardiovascular</td>
<td>- Product: Centrally acting alpha agonist, specific for 2-alpha</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Indication: Hypertension, either as monotherapy or add-on</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Market: Approximately 20mn Americans with HTN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Benefits: Specificity for 2-alpha should convey improved AE profile</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Status: IND open 2H08, begin phase II program 2H08</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- IP: Composition of matter through 2024</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Opportunity: Growing HTN market, large number of uncontrolled patients</td>
</tr>
</tbody>
</table>

Source: Company disclosures, Company website
### Sciele’s Major Pipeline Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Domain</th>
<th>Overview</th>
</tr>
</thead>
</table>
| Head Lice Treatment| Pediatrics | - First non-pesticide prescription head lice product  
- No resistance  
- Easy-to-use  
  - 10 minute application  
  - Repeat after 8 days  
  - Similar consistency to hair conditioner  
- The breathing spiracle remains open after exposure to product allowing the formulation to enter and clog the spiracle  
- The destruction of the honeycomb breathing interface is apparent |
| Xytril             | Pediatrics | - Market: 150,000 Cerebral Palsy patients  
  - Other patients with conditions such as Down’s Syndrome also require treatment to avoid severe drooling (LCM opportunity)  
  - Indicated for patients with severe drooling would limit the use to about 15% of all CP patients  
  - Other treatment choices include Scopolamine patches, etc.  
- Orphan drug status allows premium pricing (WAC $572 per pint bottle, 16 refills per year)  
- 7 Years data exclusivity  
- 15% share with favorable compliance will generate sales close to $175mn to $200mn in peak sales |

Source: Company disclosures, Company website
## R&D Partnerships

<table>
<thead>
<tr>
<th>Year</th>
<th>Partner Name</th>
<th>Product Name</th>
<th>Phase when Signed</th>
<th>Domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>Addrenex</td>
<td>ADX-415</td>
<td>Phase II</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>2007</td>
<td>Addrenex</td>
<td>CloniBID Clonicel</td>
<td>Phase III</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase II</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>2007</td>
<td>Plethora Solutions</td>
<td>PSD502</td>
<td>Phase II</td>
<td>Urology, PCP</td>
</tr>
<tr>
<td>2007</td>
<td>Summers Laboratories</td>
<td>Head Lice Treatment</td>
<td>Phase III</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>2006</td>
<td>Galephar</td>
<td>Duochol</td>
<td>Phase III</td>
<td>Cardiovascular, PCP</td>
</tr>
</tbody>
</table>

*Source: Company disclosures*
### 2009 Product Launches

<table>
<thead>
<tr>
<th>Product / Indication</th>
<th>Expected Product Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>CloniBID</td>
<td>$800 million</td>
</tr>
<tr>
<td>Hypertension (Addrenex)</td>
<td>Market Size</td>
</tr>
<tr>
<td>Xytril (orphan drug)</td>
<td>$200 million</td>
</tr>
<tr>
<td>Chronic moderate-to-severe drooling</td>
<td>Market Size</td>
</tr>
<tr>
<td>AdrenaMate</td>
<td>$225 million</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>Market Size</td>
</tr>
<tr>
<td>PSD502</td>
<td>$600 million</td>
</tr>
<tr>
<td>Premature Ejaculation (Plethora)</td>
<td>Market Size</td>
</tr>
<tr>
<td>New Prenate DHA Formulation</td>
<td>$120 million</td>
</tr>
<tr>
<td>Prenatal DHA Vitamin</td>
<td>Market Size</td>
</tr>
</tbody>
</table>

Source: Company disclosures. Market size is based on IMS Health’s NPA data